Here’s Why Traders Are Buzzing about These Five Stocks

Cisco Systems Downgraded to Neutral by Goldman Sachs

Cisco Systems, Inc. (NASDAQ:CSCO)’s stock has lost around 1.50% so far today after Goldman Sachs downgraded the stock to “Neutral” from “Buy”, while price target was lowered to $32.00 from $35.00. The firm cited lack of near term catalysts and slowing earnings growth as the reasons behind the downgrade. Donald Yacktman’s Yacktman Asset Management is one of 65 hedge funds from our system that reported stakes in Cisco Systems, Inc. (NASDAQ:CSCO) as of the end of the first quarter. It owns around 29.33 million shares of the company.

FDA Grants Three Year Market Exclusivity for Vanda Pharmaceuticals’ Drug

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)  opened lower but has inched down since the opening bell after the U.S. Food and Drug Administration (FDA) granted three years of marketing exclusivity for the changes related to the company’s supplemental New Drug Application (sNDA) for Fanapt, which was approved by the FDA last month. At the end of the first quarter, 22 funds tracked by Insider Monkey were bullish on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). James E. Flynn’s Deerfield Management owns more than 5.99 million shares of the company.

Arena Pharmaceuticals Gets New CFO

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is in the spotlight today after it announced the appointment of Kevin R. Lind as the new Executive Vice President and Chief Financial Officer of the company. In a statement, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s CEO Amit D. Munshi said that Kevin’s “significant” financial expertise and experience in healthcare environment will help the company to implement its  flexible cost structure and operating model. Only eight  funds from our database had positions in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) at the end of March. Among them, Peter Kolchinsky’s RA Capital Management owns 9.36 million shares of the company.

Disclosure: None